Seoul Pharma Statistics

Total Valuation

Seoul Pharma has a market cap or net worth of KRW 40.52 billion. The enterprise value is 49.83 billion.

Market Cap	40.52B
Enterprise Value	49.83B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Seoul Pharma has 11.66 million shares outstanding.

Current Share Class	11.66M
Shares Outstanding	11.66M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	4.73M

Valuation Ratios

The trailing PE ratio is 43.03.

PE Ratio	43.03
Forward PE	n/a
PS Ratio	0.76
PB Ratio	1.01
P/TBV Ratio	1.03
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 14.83, with an EV/FCF ratio of -6.90.

EV / Earnings	52.92
EV / Sales	0.94
EV / EBITDA	14.83
EV / EBIT	67.29
EV / FCF	-6.90

Financial Position

The company has a current ratio of 2.32, with a Debt / Equity ratio of 0.40.

Current Ratio	2.32
Quick Ratio	1.31
Debt / Equity	0.40
Debt / EBITDA	4.75
Debt / FCF	-2.21
Interest Coverage	1.68

Financial Efficiency

Return on equity (ROE) is 2.38% and return on invested capital (ROIC) is 0.87%.

Return on Equity (ROE)	2.38%
Return on Assets (ROA)	0.68%
Return on Invested Capital (ROIC)	0.87%
Return on Capital Employed (ROCE)	1.29%
Revenue Per Employee	308.35M
Profits Per Employee	5.47M
Employee Count	172
Asset Turnover	0.78
Inventory Turnover	1.73

Taxes

Income Tax	-30.79M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +4.51% in the last 52 weeks. The beta is 0.74, so Seoul Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.74
52-Week Price Change	+4.51%
50-Day Moving Average	3,346.90
200-Day Moving Average	3,569.43
Relative Strength Index (RSI)	50.95
Average Volume (20 Days)	153,175

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Seoul Pharma had revenue of KRW 53.04 billion and earned 941.67 million in profits. Earnings per share was 80.77.

Revenue	53.04B
Gross Profit	32.39B
Operating Income	740.64M
Pretax Income	910.88M
Net Income	941.67M
EBITDA	3.36B
EBIT	740.64M
Earnings Per Share (EPS)	80.77

Full Income Statement

Balance Sheet

The company has 6.64 billion in cash and 15.96 billion in debt, giving a net cash position of -9.32 billion or -799.20 per share.

Cash & Cash Equivalents	6.64B
Total Debt	15.96B
Net Cash	-9.32B
Net Cash Per Share	-799.20
Equity (Book Value)	40.01B
Book Value Per Share	3,431.40
Working Capital	18.45B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -5.06 billion and capital expenditures -2.16 billion, giving a free cash flow of -7.22 billion.

Operating Cash Flow	-5.06B
Capital Expenditures	-2.16B
Free Cash Flow	-7.22B
FCF Per Share	-619.16

Full Cash Flow Statement

Margins

Gross margin is 61.07%, with operating and profit margins of 1.40% and 1.78%.

Gross Margin	61.07%
Operating Margin	1.40%
Pretax Margin	1.72%
Profit Margin	1.78%
EBITDA Margin	6.33%
EBIT Margin	1.40%
FCF Margin	n/a

Dividends & Yields

Seoul Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	2.32%
FCF Yield	-17.82%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

The last stock split was on April 12, 2004. It was a forward split with a ratio of 2.

Last Split Date	Apr 12, 2004
Split Type	Forward
Split Ratio	2

Scores

Seoul Pharma has an Altman Z-Score of 1.98 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.98
Piotroski F-Score	4